T. Rowe Price Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$944M Sell
1,026,556
-74,308
-7% -$75.3M 0.65% 31
2025
Q4
$1.18B Buy
1,100,864
+6,168
+0.6% +$5.9M 0.75% 28
2025
Q3
$835M Buy
1,094,696
+93,659
+9% +$69.7M 0.51% 49
2025
Q2
$780M Sell
1,001,037
-114,339
-10% -$88.8M 0.49% 48
2025
Q1
$921M Buy
1,115,376
+324,598
+41% +$270M 0.61% 39
2024
Q4
$610M Buy
790,778
+14,927
+2% +$12.4M 0.38% 76
2024
Q3
$687M Sell
775,851
-213,428
-22% -$192M 0.41% 69
2024
Q2
$896M Sell
989,279
-120,355
-11% -$96.3M 0.57% 48
2024
Q1
$863M Sell
1,109,634
-2,435
-0.2% -$1.73M 0.53% 57
2023
Q4
$648M Sell
1,112,069
-194,326
-15% -$113M 0.42% 75
2023
Q3
$702M Sell
1,306,395
-6,704
-0.5% -$3.45M 0.5% 52
2023
Q2
$616M Sell
1,313,099
-13,260
-1% -$5.56M 0.42% 67
2023
Q1
$455M Buy
1,326,359
+107,400
+9% +$36.2M 0.33% 89
2022
Q4
$446M Buy
+1,218,959
New +$432M 0.34% 84

Other funds holding LLY

T. Rowe Price Investment Management's LLY Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Eli Lilly (LLY) stake by 6.7% in Q1 2026, selling an estimated $75.3M and leaving 1,026,556 shares worth $944M. The position accounts for 0.65% of the portfolio, ranked #31.

T. Rowe Price Investment Management first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.18B in Q4 2025. 4,363 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • T. Rowe Price Investment Management held 1,026,556 shares of Eli Lilly worth $944M as of Q1 2026.
  • T. Rowe Price Investment Management sold 74,308 Eli Lilly shares in Q1 2026, an estimated $75.3M.
  • Eli Lilly made up 0.65% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #31 holding.
  • T. Rowe Price Investment Management first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • T. Rowe Price Investment Management's Eli Lilly position peaked at $1.18B in Q4 2025.
  • 4,363 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.